Startup profile · funding coverage
Infinite Athlete funding, valuation and investors
Sports data OS merging live game feeds (FusionFeed) with biomechanics for leagues and broadcasters.
Keep track of Infinite Athlete
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Seed
Undisclosed · 2021
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
acquired
acquired · Los Angeles, California, USA
Investors in latest funding
Other: Andreessen Horowitz , General Catalyst
Overview
Infinite Athlete began as Tempus Ex Machina, Charlie Ebersol's sports-tech spinout from the Alliance of American Football collapse. It built FusionFeed — software that syncs disparate video and data inputs into a unified layer leagues and publishers build on. After acquiring biomechanics firm Biocore in 2023, the company rebranded to combine live performance data with player-safety research for clients including the NFL, Chelsea FC, and the Pac-12. EXOS, the human-performance company, acquired Infinite Athlete and Biocore in October 2025 to scale the technology across corporate wellness, healthcare, and military clients.
Why Infinite Athlete is interesting
FusionFeed grew from AAF wreckage into NFL back-end infrastructure — then EXOS bought the stack to push elite-sports biomechanics into corporate wellness at scale.
Product & use cases
FusionFeed syncs live video, sensor, and stats feeds into a unified sports data layer. Biocore adds biomechanical research and player-safety analytics. Leagues and broadcast partners use the combined stack for operations, content, and injury research.
- NFL gameday operations syncing video and data feeds
- Broadcast and publisher overlays built on FusionFeed APIs
- Biomechanical injury research with league safety committees
- Scaling performance analytics to corporate wellness via EXOS post-acquisition
Key facts
- Seed (2021): a16z and General Catalyst among backers when company was Tempus Ex — Sports Business Journal
- Biocore acquisition (2023): merged biomechanics research; rebranded Infinite Athlete
- Clients: NFL (FusionFeed gameday ops), Chelsea FC, Pac-12, TGL — Sports Business Journal
- Exit (Oct 2025): Acquired by EXOS; terms undisclosed — teamexos.com/newsroom
Funding history (newest first)
Investors in our directory
Funds linked from Infinite Athlete's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Deep NFL integration and Biocore's engineering research pedigree — rare combination of live data infrastructure plus peer-reviewed biomechanics under one roof.
Sports data is fragmented between rights holders, tracking vendors, and in-house league ops. Infinite Athlete's edge was a proprietary sync layer (FusionFeed) plus Biocore safety research — a combo EXOS valued for scaling beyond elite sport. Post-acquisition, the tech competes less as a standalone vendor and more as embedded infrastructure inside EXOS's performance platform.
-
Sportradar incumbent
Dominant sports data rights holder; less focused on custom fusion-layer APIs for individual leagues.
-
Second Spectrum (Genius Sports) direct
Tracking and analytics for NBA/NFL; competes on computer-vision data products.
-
Catapult Sports adjacent
Wearable athlete monitoring; overlaps on performance data but not broadcast fusion feeds.
Notable stories
- Tempus Ex Machina emerged from the 2019 collapse of Charlie Ebersol's Alliance of American Football — the same live-data tech built for AAF broadcasts became NFL infrastructure within two years.
- EXOS acquired Infinite Athlete on October 30, 2025; Charlie Ebersol became executive chairman while Biocore founder Jeff Crandall continued leading safety research — per EXOS press release.
Industries
Related funding articles
Venture Capital Tracker pieces that cover Infinite Athlete's financing or category context.
FAQs about Infinite Athlete
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.